Mary L Disis Selected Research

Neoplasm Antigens (Tumor Antigens)

5/2021	Tumor-associated autoantibodies from mouse breast cancer models are found in serum of breast cancer patients.
1/2015	Triple-negative breast cancer: immune modulation as the new treatment paradigm.
6/2013	Proteomic profiling of the autoimmune response to breast cancer antigens uncovers a suppressive effect of hormone therapy.
6/2013	T-helper I immunity, specific for the breast cancer antigen insulin-like growth factor-I receptor (IGF-IR), is associated with increased adiposity.
1/2010	Identification of a broad coverage HLA-DR degenerate epitope pool derived from carcinoembryonic antigen.
9/2009	Immunomodulation of breast cancer via tumor antigen specific Th1.
10/2008	Insulin-like growth factor-binding protein-2 is a target for the immunomodulation of breast cancer.
4/2008	Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancer.
3/2008	Level of HER-2/neu protein expression in breast cancer may affect the development of endogenous HER-2/neu-specific immunity.
8/2007	Functional T cell responses to tumor antigens in breast cancer patients have a distinct phenotype and cytokine signature.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mary L Disis Research Topics

Disease

129	Neoplasms (Cancer) 02/2022 - 01/2002
59	Breast Neoplasms (Breast Cancer) 02/2022 - 01/2002
20	Ovarian Neoplasms (Ovarian Cancer) 01/2022 - 06/2002
5	Triple Negative Breast Neoplasms 01/2021 - 08/2015
5	Neoplasm Metastasis (Metastasis) 01/2020 - 10/2005
5	Carcinoma (Carcinomatosis) 12/2013 - 04/2006
4	Carcinogenesis 05/2021 - 08/2014
4	Human Influenza (Influenza) 01/2017 - 05/2002
4	Inflammation (Inflammations) 01/2017 - 11/2009
3	Colorectal Neoplasms (Colorectal Cancer) 01/2021 - 02/2007
3	Disease Progression 01/2019 - 07/2006
3	Squamous Cell Carcinoma of Head and Neck 05/2017 - 01/2016
3	Hypersensitivity (Allergy) 12/2009 - 07/2002
2	Noninfiltrating Intraductal Carcinoma (DCIS) 02/2022 - 05/2021
2	Colonic Neoplasms (Colon Cancer) 01/2022 - 01/2021
2	Melanoma (Melanoma, Malignant) 12/2020 - 01/2015
2	Lung Neoplasms (Lung Cancer) 01/2019 - 11/2016
2	Infections 02/2017 - 04/2015
2	Glioblastoma (Glioblastoma Multiforme) 02/2017 - 07/2003
2	Autoimmune Diseases (Autoimmune Disease) 01/2017 - 02/2016
2	Obesity 01/2017 - 06/2013
2	Communicable Diseases (Infectious Diseases) 01/2017 - 04/2008
2	Neoplasm Micrometastasis 12/2013 - 03/2012
2	Prostatic Neoplasms (Prostate Cancer) 06/2010 - 01/2003
2	Testicular Neoplasms (Testicular Cancer) 10/2005 - 09/2005
1	Polyps 01/2022

Drug/Important Bio-Agent (IBA)

49	AntigensIBA 02/2022 - 01/2002
45	VaccinesIBA 02/2022 - 03/2002
36	Proteins (Proteins, Gene)FDA Link 02/2022 - 01/2002
22	Peptides (Polypeptides)IBA 01/2021 - 04/2002
20	Neoplasm Antigens (Tumor Antigens)IBA 05/2021 - 06/2002
18	EpitopesIBA 12/2021 - 07/2002
17	Biomarkers (Surrogate Marker)IBA 12/2018 - 02/2007
14	CytokinesIBA 12/2021 - 03/2002
12	Cancer VaccinesIBA 04/2017 - 10/2005
10	AntibodiesIBA 01/2020 - 03/2003
9	Immunoglobulin G (IgG)IBA 05/2021 - 03/2003
7	Insulin-Like Growth Factor Binding Protein 2IBA 12/2021 - 05/2008
7	Immune Checkpoint InhibitorsIBA 01/2021 - 10/2014
7	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 01/2017 - 05/2002
6	AutoantibodiesIBA 05/2021 - 04/2008
5	RNA (Ribonucleic Acid)IBA 01/2022 - 10/2005
4	Insulin-Like PeptidesIBA 12/2021 - 06/2008
4	LigandsIBA 01/2021 - 10/2005
4	Biological ProductsIBA 01/2019 - 01/2011
4	Monoclonal AntibodiesIBA 01/2016 - 02/2004
4	HLA-DR Antigens (HLA-DR)IBA 02/2010 - 01/2006
4	EnzymesIBA 02/2010 - 03/2002
3	PlatinumIBA 01/2021 - 01/2017
3	Estrogen ReceptorsIBA 01/2020 - 10/2006
3	Messenger RNA (mRNA)IBA 01/2020 - 11/2006
3	VTX-2337IBA 01/2018 - 01/2016
3	Imiquimod (Aldara)FDA LinkGeneric 07/2017 - 05/2010
3	Oncogene Proteins (Oncogene Protein)IBA 11/2016 - 01/2005
3	Hormones (Hormone)IBA 10/2016 - 06/2013
3	Interleukin-2 (IL2)IBA 01/2016 - 07/2006
3	Protein Subunit VaccinesIBA 08/2014 - 07/2002
3	AlginatesIBA 02/2014 - 08/2010
3	ChitosanIBA 02/2014 - 08/2010
3	ImmunosorbentsIBA 02/2010 - 05/2002
3	HLA-A2 Antigen (HLA A2 Antigen)IBA 03/2003 - 05/2002
2	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 01/2022 - 08/2013
2	Pharmaceutical PreparationsIBA 01/2022 - 12/2011
2	Small Interfering RNA (siRNA)IBA 01/2022 - 01/2006
2	Phenobarbital (Luminal)FDA Link 01/2020 - 01/2017
2	Complementary DNA (cDNA)IBA 12/2019 - 03/2003
2	ChemokinesIBA 01/2019 - 02/2014
2	Indicators and Reagents (Reagents)IBA 01/2019 - 02/2006
2	CarcinogensIBA 01/2019 - 12/2014
2	Tumor Biomarkers (Tumor Markers)IBA 12/2018 - 09/2011
2	130-nm albumin-bound paclitaxelIBA 07/2017 - 01/2017
2	Toll-Like Receptors (Toll-Like Receptor)IBA 07/2017 - 05/2017
2	Albumin-Bound Paclitaxel FDA Link 07/2017 - 01/2017
2	Cetuximab (Erbitux)FDA Link 05/2017 - 01/2016
2	Toll-Like Receptor AgonistsIBA 05/2017 - 05/2010
2	InterferonsIBA 02/2017 - 06/2009
2	AutoantigensIBA 01/2017 - 10/2014
2	ErbB Receptors (EGF Receptor)IBA 11/2016 - 01/2016
2	Interleukin-12 (IL 12)IBA 01/2016 - 05/2007
2	polysaccharide-KIBA 08/2013 - 01/2011
2	Trastuzumab (Herceptin)FDA Link 11/2011 - 10/2009
2	human ERBB2 proteinIBA 06/2010 - 10/2009
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 05/2010 - 05/2007
2	Transforming Growth Factor beta (TGF-beta)IBA 11/2009 - 10/2009
2	flt3 ligand protein (flt3 ligand)IBA 01/2003 - 04/2002
1	epacadostatIBA 01/2022
1	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 01/2022
1	Anti-Inflammatory Agents (Anti-Inflammatories)IBA 01/2022
1	Naproxen (Naprosyn)FDA LinkGeneric 01/2022
1	Celecoxib (Celebrex)FDA Link 01/2022
1	Immune Checkpoint ProteinsIBA 01/2022
1	Indoleamine-Pyrrole 2,3,-Dioxygenase (Indoleamine 2,3 Dioxygenase)IBA 01/2022
1	Immunomodulating AgentsIBA 12/2021
1	DNA VaccinesIBA 12/2021

Therapy/Procedure

37	Therapeutics 02/2022 - 01/2002
35	Immunotherapy 01/2021 - 01/2002
10	Drug Therapy (Chemotherapy) 02/2022 - 01/2004
6	Biological Therapy 09/2011 - 03/2002
5	Chemoprevention 01/2022 - 04/2010
4	Immunomodulation 02/2018 - 10/2008